Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,467 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404.
Shien T, Iwata H, Fukutomi T, Inoue K, Aogi K, Kinoshita T, Ando J, Takashima S, Nakamura K, Shibata T, Fukuda H. Shien T, et al. Among authors: kinoshita t. Cancer Chemother Pharmacol. 2014 Sep;74(3):603-9. doi: 10.1007/s00280-014-2545-2. Epub 2014 Jul 24. Cancer Chemother Pharmacol. 2014. PMID: 25055938 Free PMC article. Clinical Trial.
A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017.
Shien T, Nakamura K, Shibata T, Kinoshita T, Aogi K, Fujisawa T, Masuda N, Inoue K, Fukuda H, Iwata H. Shien T, et al. Among authors: kinoshita t. Jpn J Clin Oncol. 2012 Oct;42(10):970-3. doi: 10.1093/jjco/hys120. Epub 2012 Jul 24. Jpn J Clin Oncol. 2012. PMID: 22833684 Clinical Trial.
Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401).
Shien T, Iwata H, Aogi K, Fukutomi T, Inoue K, Kinoshita T, Takahashi M, Matsui A, Shibata T, Fukuda H. Shien T, et al. Among authors: kinoshita t. Int J Clin Oncol. 2014 Dec;19(6):982-8. doi: 10.1007/s10147-013-0657-z. Epub 2014 Jan 7. Int J Clin Oncol. 2014. PMID: 24395447 Clinical Trial.
Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome.
Shien T, Shimizu C, Seki K, Shibata T, Hojo T, Ando M, Kohno T, Katsumata N, Akashi-Tanaka S, Kinoshita T, Fujiwara Y. Shien T, et al. Among authors: kinoshita t. Breast Cancer Res Treat. 2009 Jan;113(2):307-13. doi: 10.1007/s10549-008-9935-2. Epub 2008 Feb 20. Breast Cancer Res Treat. 2009. PMID: 18286370
Intensive vs. Standard Post-Operative Surveillance in High-Risk Breast Cancer Patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204.
Hojo T, Masuda N, Mizutani T, Shibata T, Kinoshita T, Tamura K, Hara F, Fujisawa T, Inoue K, Saji S, Nakamura K, Fukuda H, Iwata H. Hojo T, et al. Among authors: kinoshita t. Jpn J Clin Oncol. 2015 Oct;45(10):983-6. doi: 10.1093/jjco/hyv110. Epub 2015 Aug 5. Jpn J Clin Oncol. 2015. PMID: 26246481 Clinical Trial.
3,467 results